Revvity (NYSE:RVTY) PT Raised to $135.00 at Leerink Partners

Revvity (NYSE:RVTY) had its target price upped by stock analysts at Leerink Partners from $130.00 to $135.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ price objective would suggest a potential upside of 12.81% from the company’s current price.

RVTY has been the topic of several other research reports. Citigroup upped their price target on Revvity from $135.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Jefferies Financial Group upped their target price on shares of Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 29th. Leerink Partnrs upgraded shares of Revvity to a “strong-buy” rating in a research note on Monday, July 8th. Barclays raised shares of Revvity from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $125.00 to $140.00 in a research report on Tuesday. Finally, TD Cowen lifted their price objective on shares of Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $127.20.

Revvity Stock Up 0.6 %

Shares of RVTY opened at $119.67 on Thursday. The company’s 50-day simple moving average is $121.61 and its 200-day simple moving average is $112.98. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. Revvity has a 1 year low of $79.50 and a 1 year high of $128.15. The stock has a market capitalization of $14.77 billion, a PE ratio of 98.90, a P/E/G ratio of 3.35 and a beta of 1.05.

Revvity (NYSE:RVTY) last released its earnings results on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The company had revenue of $691.70 million for the quarter, compared to analyst estimates of $690.33 million. During the same period in the prior year, the business earned $1.21 EPS. The firm’s quarterly revenue was down 2.5% on a year-over-year basis. Analysts forecast that Revvity will post 4.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Tajinder S. Vohra sold 2,154 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the sale, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Revvity news, insider Joel S. Goldberg sold 3,500 shares of the firm’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the transaction, the insider now directly owns 33,400 shares of the company’s stock, valued at approximately $3,936,524. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Tajinder S. Vohra sold 2,154 shares of the company’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now directly owns 19,652 shares of the company’s stock, valued at $2,392,237.96. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 7,807 shares of company stock valued at $937,576 over the last quarter. Company insiders own 0.60% of the company’s stock.

Hedge Funds Weigh In On Revvity

Hedge funds and other institutional investors have recently made changes to their positions in the stock. UniSuper Management Pty Ltd lifted its position in Revvity by 505.2% during the 1st quarter. UniSuper Management Pty Ltd now owns 9,864 shares of the company’s stock worth $1,036,000 after acquiring an additional 8,234 shares during the period. Entropy Technologies LP acquired a new stake in shares of Revvity during the first quarter worth $480,000. Jane Street Group LLC lifted its holdings in shares of Revvity by 516.4% during the first quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after purchasing an additional 379,802 shares during the period. Quadrature Capital Ltd purchased a new position in Revvity in the 1st quarter valued at $1,267,000. Finally, Assenagon Asset Management S.A. increased its stake in Revvity by 3,171.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 87,180 shares of the company’s stock valued at $9,142,000 after buying an additional 84,515 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.